Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

PEN

Penumbra Inc

Jan 15 • 04:00PM ET

350.49

+37.06 11.82 %

Healthcare • Medical Devices • USA • NYSE

Jan 15, 10:40 AMBoston Scientific to acquire Penumbra for $374 per share in a deal valuing Penumbra at about $14.6B, with holders able to elect cash or 3.8721 Boston Scientific shares per PEN share; Penumbra also issued preliminary results calling for Q4 revenue of $383–$385M (+21%–22% YoY) and 2025 revenue of ~$1.40B (+17% YoY) with mid-teens operating margins.

Peers: BSX ISRG EW HOLX MDT JNJ ABT SYK ZBH TFX

| Held by: IJH VTI VB VBK VXF XMHQ MDY IWP XMMO IJK

Scroll to Statements

Index	-	P/E	83.76	EPS (ttm)	4.18	Insider Own	3.08%	Shs Outstand	39.15M	Perf Week	11.08%
Market Cap	13.73B	Forward P/E	69.47	EPS next Y	5.05	Insider Trans	-8.67%	Shs Float	37.96M	Perf Month	13.37%
Enterprise Value	13.47B	PEG	1.63	EPS next Q	1.10	Inst Own	94.47%	Short Float	4.50%	Perf Quarter	38.75%
Income	164.03M	P/S	10.29	EPS this Y	69.96%	Inst Trans	2.75%	Short Ratio	3.40	Perf Half Y	52.32%
Sales	1.33B	P/B	10.10	EPS next Y	33.72%	ROA	10.18%	Short Interest	1.71M	Perf YTD	12.73%
Book/sh	34.70	P/C	29.19	EPS next 5Y	42.61%	ROE	13.32%	52W High	325.02 7.83%	Perf Year	38.59%
Cash/sh	12.01	P/FCF	89.94	EPS past 3/5Y	36.76% -23.21%	ROIC	10.51%	52W Low	221.26 58.41%	Perf 3Y	51.01%
Dividend Est.	-	EV/EBITDA	69.54	Sales past 3/5Y	16.91% 16.89%	Gross Margin	66.60%	Volatility	5.17% 3.12%	Perf 5Y	77.27%
Dividend TTM	-	EV/Sales	10.10	EPS Y/Y TTM	369.96%	Oper. Margin	12.95%	ATR (14)	13.00	Perf 10Y	554.39%
Dividend Ex-Date	-	Quick Ratio	4.18	Sales Y/Y TTM	14.61%	Profit Margin	12.30%	RSI (14)	70.58	Recom	1.75
Dividend Gr. 3/5Y	- -	Current Ratio	6.73	EPS Q/Q	54.78%	SMA20	10.74%	Beta	0.81	Target Price	352.88
Payout	0.00%	Debt/Eq	0.16	Sales Q/Q	17.82%	SMA50	17.69%	Rel Volume	19.26	Prev Close	313.43
Employees	4500	LT Debt/Eq	0.15	Earnings	Nov 05 AMC	SMA200	30.11%	Avg Volume	502.44K	Price	350.49
IPO	Sep 18, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.45% 4.03%	Trades		Volume	9,674,574	Change	11.82%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-18-25	Upgrade	JP Morgan	Neutral → Overweight	$370
Dec-11-25	Upgrade	Citigroup	Neutral → Buy	$350
Nov-18-25	Initiated	Wells Fargo	Underweight	$15
Oct-08-25	Upgrade	Needham	Hold → Buy	$326
Sep-02-25	Initiated	Evercore ISI	Outperform	$300
Mar-14-25	Initiated	BofA Securities	Buy	$320
Jan-21-25	Initiated	UBS	Buy	$305
Dec-17-24	Initiated	Oppenheimer	Outperform	$275
Dec-11-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$190 → $275
Sep-18-24	Initiated	Stifel	Buy	$238
Sep-03-24	Initiated	Leerink Partners	Outperform	$263
Jul-31-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$289 → $150
Jul-31-24	Downgrade	Citigroup	Buy → Neutral	$165 → $178
Feb-23-24	Downgrade	JP Morgan	Overweight → Neutral	$284 → $250
Sep-06-23	Initiated	Morgan Stanley	Equal-Weight	$265
Jul-19-23	Initiated	Robert W. Baird	Outperform	$375
Mar-29-23	Downgrade	Needham	Buy → Hold
Jan-30-23	Initiated	Piper Sandler	Overweight	$275
Nov-04-22	Upgrade	Citigroup	Neutral → Buy	$217 → $212
Oct-12-22	Initiated	Jefferies	Buy	$230

Show Previous Ratings

Today 06:35PM	Analyst Report: Penumbra, Inc. (Morningstar Research) +11.82%
05:34PM	Podcast: Chips, Banks Boost Markets (The Wall Street Journal)
04:33PM	Stocks Boosted by Chip Demand Optimism (Barchart)
04:25PM	Stocks to Watch Thursday: Penumbra, BlackRock, Goldman Sachs (The Wall Street Journal)
04:16PM	Lightning Flashes As Boston Scientific Takes Over Penumbra For $14.5 Billion (Investor's Business Daily)
01:23PM	Loading…
01:23PM	JPM26: Boston Scientific acquires Penumbra in $14.5bn deal (Medical Device Network)
01:11PM	Wall Street Soars Near Records, AMD And ASML Jump 6%: What's Moving Markets Thursday? (Benzinga)
12:51PM	Why Penumbra (PEN) Stock Is Trading Up Today (StockStory)
10:17AM	Boston Scientific Agrees to Buy Penumbra in $14.6 Billion Cardiovascular Deal (GuruFocus.com)
09:37AM	Stocks to Watch Thursday: Goldman Sachs, Boston Scientific, BlackRock (The Wall Street Journal)
09:23AM	BlackRock earnings, Spotify to raise premium price in the US (Yahoo Finance Video)
09:03AM	Boston Scientific Will Buy Penumbra In $14.5 Billion Medtech Deal (Investor's Business Daily)
08:45AM	Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion. (Barrons.com)
08:42AM	Boston Scientific Acquires Penumbra In $14.5 Billion Bet To Dominate Thrombectomy (Benzinga)
08:38AM	Penumbra surges on news of $14.5 billion Boston Scientific buyout, BSX down (Investing.com)
08:11AM	Loading…
08:11AM	Boston Scientific is buying Penumbra for $14.5 billion, gaining entry to 'fast-growing' vascular segments (MarketWatch)
07:25AM	Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock (The Wall Street Journal)
07:13AM	Boston Scientific to buy Penumbra in $14.5 billion deal (Reuters)
07:00AM	Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results (PR Newswire)
07:00AM	Boston Scientific announces agreement to acquire Penumbra, Inc. (PR Newswire)
Jan-13-26 01:04PM	Silver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday? (Benzinga) -5.79%
Jan-12-26 11:40AM	CLPBY vs. PEN: Which Stock Is the Better Value Option? (Zacks)
09:50AM	Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term (Zacks)
Jan-07-26 12:45PM	Penumbra (PEN) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
Dec-31-25 09:45AM	Here's Why Penumbra (PEN) is a Strong Growth Stock (Zacks)
Dec-29-25 04:30PM	Penumbra, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-26-25 07:17AM	Reasons to Retain Penumbra Stock in Your Portfolio for Now (Zacks)
Dec-22-25 07:30AM	NeuroOne(R) Appoints Jason Mills to the Board of Directors (NewMediaWire)
Dec-19-25 04:05PM	Stocks At New Highs: Industrials Allient, Wabtec And A Health Care Name Trade In Or Near Buy Zones (Investor's Business Daily)
Dec-15-25 09:45AM	Here's Why Penumbra (PEN) is a Strong Growth Stock (Zacks)
01:55PM	Loading…
Dec-11-25 01:55PM	Stock Market Today: Dow Jumps, Nasdaq Trims Losses; Boot Barn, ATI, Penumbra Shares Break Out (Live Coverage) (Investor's Business Daily)
Dec-10-25 11:33PM	3 Profitable Stocks That Fall Short (StockStory) +5.55%
Dec-05-25 04:29PM	IBD Stock Of The Day Breaks Out, Lays The Groundwork For 2026 Acceleration (Investor's Business Daily)
01:44PM	IBD Stock Of The Day Penumbra Lays The Groundwork For 2026 Acceleration (Investor's Business Daily)
Dec-03-25 11:40AM	GMED or PEN: Which Is the Better Value Stock Right Now? (Zacks)
Nov-27-25 09:45AM	Here's Why Penumbra (PEN) is a Strong Growth Stock (Zacks)
Nov-25-25 10:31PM	Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q3 In Review: Penumbra (NYSE:PEN) Vs Peers (StockStory)
Nov-24-25 06:36PM	Analyst Report: Penumbra, Inc. (Morningstar Research)
Nov-21-25 06:50PM	Penumbra, Corcept, Elanco, ResMed, and LeMaitre Stocks Trade Up, What You Need To Know (StockStory)
Nov-19-25 04:30PM	Penumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference (PR Newswire)
Nov-18-25 09:50AM	Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-11-25 11:36PM	2 Healthcare Stocks to Keep an Eye On and 1 We Find Risky (StockStory)
07:55AM	Penumbra Stock Up Post Q3 Earnings & Revenue Beat, Margins Expand (Zacks)
Nov-10-25 02:26PM	Do Options Traders Know Something About Penumbra Stock We Don't? (Zacks)
09:45AM	Why Penumbra (PEN) is a Top Growth Stock for the Long-Term (Zacks)
Nov-07-25 08:45AM	Penumbra price target raised to $355 from $350 at Canaccord (TipRanks)
Nov-06-25 04:02PM	Penumbra Shoots For A Breakout On 'Another Impressive Quarter' (Investor's Business Daily) +17.32%
11:36AM	Why Penumbra (PEN) Stock Is Up Today (StockStory)
09:01AM	Analyst Report: Penumbra, Inc. (Morningstar Research)
12:03AM	Penumbra Inc (PEN) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and New Product ... (GuruFocus.com)
Nov-05-25 06:30PM	Penumbra (PEN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:00PM	Penumbra (PEN) Q3 Earnings and Revenues Beat Estimates (Zacks)
05:12PM	Penumbra (NYSE:PEN) Delivers Strong Q3 Numbers, Stock Jumps 18.7% (StockStory)
04:56PM	Penumbra: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Penumbra, Inc. Reports Third Quarter 2025 Financial Results (PR Newswire)
Nov-03-25 10:12PM	What To Expect From Penumbra's (PEN) Q3 Earnings (StockStory)
03:00PM	Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism (PR Newswire)
Oct-28-25 03:20PM	Why Penumbra (PEN) Shares Are Falling Today (StockStory) -5.04%
Oct-27-25 09:00AM	Landmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism (PR Newswire)
Oct-26-25 05:00PM	Can Penumbra's 'Landmark' Study Vs. Blood Thinners Change Guidelines? (Investor's Business Daily)
Oct-20-25 06:31AM	Needham Upgrades Penumbra (PEN) to Buy Amid 2026 Growth Outlook (Insider Monkey)
Oct-13-25 11:40AM	ITGR or PEN: Which Is the Better Value Stock Right Now? (Zacks)
Oct-08-25 04:30PM	Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025 (PR Newswire)
11:35AM	Penumbra (PEN) Stock Trades Up, Here Is Why (StockStory)
09:45AM	Intel, FedEx downgraded: Wall Street's top analyst calls (The Fly)
Oct-01-25 01:58PM	Penumbra, Inc. (PEN) Promotes Shruthi Narayan to President to Drive Global Growth (Insider Monkey)
Sep-24-25 11:40AM	TFX vs. PEN: Which Stock Should Value Investors Buy Now? (Zacks)
Sep-18-25 08:48AM	What Makes Penumbra (PEN) a Good Investment? (Insider Monkey)
Sep-12-25 08:14PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Sep-09-25 09:00AM	New Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk Profile (PR Newswire)
Sep-06-25 10:44PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Sep-02-25 09:45AM	Elf Beauty downgraded, Zscaler upgraded: Wall Street's top analyst calls (The Fly)
Aug-29-25 11:30AM	Why Is TransMedics (TMDX) Down 1.9% Since Last Earnings Report? (Zacks)
Aug-28-25 11:30AM	Why Is Penumbra (PEN) Up 5% Since Last Earnings Report? (Zacks)
Aug-27-25 11:34PM	Spotting Winners: Penumbra (NYSE:PEN) And Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks In Q2 (StockStory)
09:00AM	Penumbra, Inc. Names Shruthi Narayan as Company President (PR Newswire)
Aug-22-25 12:01AM	Penumbra (PEN): Buy, Sell, or Hold Post Q2 Earnings? (StockStory) +5.32%
Aug-20-25 04:30PM	Penumbra, Inc. to Present at Upcoming Investor Conferences (PR Newswire)
Aug-19-25 11:40AM	ITGR or PEN: Which Is the Better Value Stock Right Now? (Zacks)
Aug-13-25 05:50PM	Penumbra, STAAR Surgical, CONMED, Acadia Healthcare, and Select Medical Shares Are Soaring, What You Need To Know (StockStory)
Aug-12-25 12:52AM	PEN Q2 Deep Dive: Sales Force Expansion and Clinical Milestones Drive Outperformance (StockStory)
12:42AM	5 Insightful Analyst Questions From Penumbra's Q2 Earnings Call (StockStory)
Jul-31-25 08:59AM	Should You Invest in Penumbra (PEN)? (Insider Monkey)
Jul-30-25 04:30PM	Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference (PR Newswire) +11.91%
01:40PM	Penumbra (PEN) Shares Skyrocket, What You Need To Know (StockStory)
03:16AM	Penumbra Inc (PEN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Jul-29-25 05:30PM	Penumbra (PEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:27PM	Penumbra's (NYSE:PEN) Q2: Strong Sales, Stock Soars (StockStory)
05:20PM	Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
04:18PM	Penumbra: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Penumbra, Inc. Reports Second Quarter 2025 Financial Results (PR Newswire)
11:40AM	ITGR vs. PEN: Which Stock Is the Better Value Option? (Zacks)
Jul-27-25 11:08PM	Penumbra (PEN) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Jul-24-25 12:10PM	Will Penumbra (PEN) Beat Estimates Again in Its Next Earnings Report? (Zacks)
10:00AM	Mettler-Toledo (MTD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-22-25 10:00AM	Penumbra (PEN) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-11-25 11:40AM	ITGR or PEN: Which Is the Better Value Stock Right Now? (Zacks)
Jul-10-25 12:39AM	Penumbra (PEN) Announces Completion of Enrollment in STORM-PE Clinical Trial (Insider Monkey)
Jul-01-25 04:30PM	Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025 (PR Newswire)
Jun-25-25 11:40AM	ITGR vs. PEN: Which Stock Is the Better Value Option? (Zacks)

Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Grewal Harpreet	Director	Jan 06 '26	Sale	312.64	186	58,151	8,230	Jan 08 09:06 PM
Wilder Thomas	Director	Jan 02 '26	Sale	310.72	186	57,794	0	Jan 06 07:33 PM
Grewal Harpreet	Director	Jan 06 '26	Proposed Sale	312.64	186	58,151		Jan 06 03:52 PM
THOMAS WILDER	Director	Jan 02 '26	Proposed Sale	310.72	186	57,794		Jan 02 04:02 PM
Bose Arani	Director	Dec 11 '25	Sale	308.82	15,000	4,632,292	258,462	Dec 15 07:30 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Dec 05 '25	Sale	300.13	300	90,039	63,836	Dec 09 08:01 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Dec 01 '25	Sale	294.94	600	176,966	64,136	Dec 03 07:45 PM
Grewal Harpreet	Director	Dec 02 '25	Sale	292.98	100	29,298	8,416	Dec 03 07:44 PM
Grewal Harpreet	Director	Dec 02 '25	Proposed Sale	292.98	100	29,298		Dec 02 03:59 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Nov 25 '25	Sale	300.06	1,800	540,108	64,736	Nov 26 07:36 PM
Bose Arani	Director	Nov 25 '25	Sale	300.19	7,500	2,251,425	275,261	Nov 26 07:36 PM
Bose Arani	Director	Nov 21 '25	Sale	290.56	7,500	2,179,212	282,761	Nov 25 07:59 PM
Johanna Roberts	Officer	Nov 25 '25	Proposed Sale	298.11	2,100	626,031		Nov 25 05:20 PM
Arani Bose	Affiliate	Nov 21 '25	Proposed Sale	279.79	30,000	8,393,700		Nov 21 05:21 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Nov 10 '25	Sale	266.98	600	160,189	63,657	Nov 12 07:32 PM
Grewal Harpreet	Director	Nov 04 '25	Sale	227.58	186	42,330	8,516	Nov 06 07:31 PM
Grewal Harpreet	Director	Nov 04 '25	Proposed Sale	227.58	186	42,330		Nov 04 03:53 PM
Grewal Harpreet	Director	Oct 02 '25	Sale	248.61	186	46,241	8,702	Oct 03 07:32 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Oct 01 '25	Sale	249.70	600	149,820	64,257	Oct 03 07:31 PM
Wilder Thomas	Director	Oct 01 '25	Sale	253.93	186	47,231	186	Oct 03 07:30 PM
Grewal Harpreet	Director	Oct 02 '25	Proposed Sale	248.61	186	46,241		Oct 02 04:03 PM
Johanna Roberts	Officer	Oct 01 '25	Proposed Sale	253.22	1,800	455,796		Oct 01 04:08 PM
THOMAS WILDER	Director	Oct 01 '25	Proposed Sale	253.93	186	47,231		Oct 01 04:01 PM
Grewal Harpreet	Director	Sep 02 '25	Sale	272.19	186	50,627	8,888	Sep 04 07:36 PM
Elsesser Adam	CEO	Sep 03 '25	Option Exercise	30.00	27,980	839,400	198,260	Sep 04 07:36 PM
Elsesser Adam	CEO	Sep 03 '25	Sale	269.65	15,800	4,260,457	182,460	Sep 04 07:36 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Sep 02 '25	Sale	270.58	600	162,347	64,857	Sep 04 07:36 PM
ADAM ELSESSER	Officer	Sep 03 '25	Proposed Sale	269.65	15,800	4,260,404		Sep 03 04:51 PM
Grewal Harpreet	Director	Sep 02 '25	Proposed Sale	272.19	186	50,627		Sep 02 03:59 PM
Elsesser Adam	CEO and President	Aug 20 '25	Option Exercise	30.00	27,976	839,280	186,180	Aug 22 07:48 PM
Elsesser Adam	CEO and President	Aug 20 '25	Sale	254.53	15,900	4,046,952	170,280	Aug 22 07:48 PM
ADAM ELSESSER	Officer	Aug 20 '25	Proposed Sale	254.53	15,900	4,046,989		Aug 20 04:28 PM
Yuen Maggie	Chief Financial Officer	Aug 15 '25	Option Exercise	158.30	724	114,609	13,667	Aug 15 07:49 PM
Yuen Maggie	Chief Financial Officer	Aug 13 '25	Sale	250.00	2,000	500,000	12,943	Aug 15 07:49 PM
Bose Arani	Director	Aug 13 '25	Sale	250.65	12,000	3,007,776	558	Aug 15 07:44 PM
Wilder Thomas	Director	Aug 12 '25	Sale	240.16	372	89,340	372	Aug 13 07:44 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Aug 11 '25	Sale	238.94	600	143,363	65,457	Aug 13 07:40 PM
Arani Bose	Affiliate	Aug 13 '25	Proposed Sale	248.55	12,000	2,982,600		Aug 13 05:24 PM
MAGGIE YUEN	Officer	Aug 13 '25	Proposed Sale	250.00	2,000	500,000		Aug 13 04:04 PM
THOMAS WILDER III	Director	Aug 12 '25	Proposed Sale	240.16	372	89,340		Aug 12 04:05 PM
Elsesser Adam	CEO and President	Aug 06 '25	Option Exercise	30.00	27,976	839,280	174,234	Aug 08 08:06 PM
Elsesser Adam	CEO and President	Aug 06 '25	Sale	238.20	16,030	3,818,363	158,204	Aug 08 08:06 PM
ADAM ELSESSER	Officer	Aug 06 '25	Proposed Sale	238.20	16,030	3,818,397		Aug 06 04:48 PM
Elsesser Adam	CEO and President	Jul 23 '25	Option Exercise	30.00	27,976	839,280	162,408	Jul 25 07:32 PM
Elsesser Adam	CEO and President	Jul 23 '25	Sale	233.16	16,150	3,765,574	146,258	Jul 25 07:32 PM
ADAM ELSESSER	Officer	Jul 23 '25	Proposed Sale	233.16	16,150	3,765,610		Jul 23 04:15 PM
Elsesser Adam	CEO and President	Jul 09 '25	Option Exercise	30.00	27,976	839,280	150,417	Jul 11 07:30 PM
Elsesser Adam	CEO and President	Jul 09 '25	Sale	243.75	15,985	3,896,344	134,432	Jul 11 07:30 PM
ADAM ELSESSER	Officer	Jul 09 '25	Proposed Sale	243.75	15,985	3,896,329		Jul 09 04:27 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Jul 01 '25	Sale	252.70	600	151,622	66,057	Jul 03 07:54 PM
Johanna Roberts	Officer	Jul 01 '25	Proposed Sale	256.63	3,000	769,890		Jul 01 04:51 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Jun 25 '25	Option Exercise	22.04	1,943	42,824	66,657	Jun 27 08:04 PM
Elsesser Adam	CEO and President	Jun 25 '25	Option Exercise	30.00	27,976	839,280	138,331	Jun 27 08:02 PM
Elsesser Adam	CEO and President	Jun 25 '25	Sale	253.40	15,890	4,026,589	122,441	Jun 27 08:02 PM
ADAM ELSESSER	Officer	Jun 25 '25	Proposed Sale	253.40	15,890	4,026,585		Jun 25 04:25 PM
O'Rourke Bridget	Director	Jun 16 '25	Sale	259.78	50	12,989	5,373	Jun 18 07:46 PM
BRIDGET A O'ROURKE	Director	Jun 16 '25	Proposed Sale	259.78	50	12,989		Jun 16 04:05 PM
Elsesser Adam	CEO and President	Jun 11 '25	Option Exercise	30.00	27,976	839,280	126,265	Jun 13 07:33 PM
Elsesser Adam	CEO and President	Jun 11 '25	Sale	253.67	15,910	4,035,890	110,355	Jun 13 07:33 PM
ADAM ELSESSER	Officer	Jun 11 '25	Proposed Sale	253.67	15,910	4,035,902		Jun 11 05:09 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Jun 02 '25	Sale	258.17	600	154,903	64,714	Jun 04 07:30 PM
Elsesser Adam	CEO and President	May 28 '25	Option Exercise	30.00	27,976	839,280	114,589	May 30 08:02 PM
Elsesser Adam	CEO and President	May 28 '25	Sale	267.91	16,300	4,366,920	98,289	May 30 08:02 PM
ADAM ELSESSER	Officer	May 28 '25	Proposed Sale	267.91	16,300	4,366,915		May 28 04:08 PM
Elsesser Adam	CEO and President	May 14 '25	Option Exercise	30.00	27,976	839,280	103,213	May 16 07:35 PM
Elsesser Adam	CEO and President	May 14 '25	Sale	298.22	16,600	4,950,476	86,613	May 16 07:35 PM
O'Rourke Bridget	Director	May 15 '25	Sale	286.15	100	28,615	5,423	May 16 07:33 PM
BRIDGET A O'ROURKE	Director	May 15 '25	Proposed Sale	286.15	100	28,615		May 15 04:03 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	May 12 '25	Option Exercise	22.04	55	1,212	66,214	May 14 07:53 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	May 12 '25	Sale	298.55	900	268,698	65,314	May 14 07:53 PM
ADAM ELSESSER	Officer	May 14 '25	Proposed Sale	298.22	16,600	4,950,469		May 14 04:22 PM
Elsesser Adam	CEO and President	May 07 '25	Option Exercise	30.00	27,976	839,280	91,887	May 09 07:35 PM
Elsesser Adam	CEO and President	May 07 '25	Sale	289.37	16,650	4,818,006	75,237	May 09 07:35 PM
ADAM ELSESSER	Officer	May 07 '25	Proposed Sale	289.35	16,650	4,817,704		May 07 04:44 PM
Yuen Maggie	Chief Financial Officer	May 06 '25	Option Exercise	158.30	900	142,470	14,857	May 06 07:30 PM
Yuen Maggie	Chief Financial Officer	May 02 '25	Sale	299.01	2,000	598,020	13,957	May 06 07:30 PM
MAGGIE YUEN	Officer	May 02 '25	Proposed Sale	299.01	2,000	598,020		May 02 04:06 PM
Bose Arani	Director	Apr 25 '25	Sale	298.73	12,000	3,584,775	302,819	Apr 29 07:34 PM
Kassing Don W.	Director	Apr 29 '25	Proposed Sale	277.35	8,500	2,357,475		Apr 29 05:32 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Apr 24 '25	Option Exercise	22.04	600	13,224	66,759	Apr 25 07:55 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Apr 24 '25	Sale	300.01	600	180,006	66,159	Apr 25 07:55 PM
Elsesser Adam	CEO and President	Apr 16 '25	Option Exercise	30.00	27,976	839,280	80,471	Apr 18 07:38 PM
Elsesser Adam	CEO and President	Apr 16 '25	Sale	274.35	16,560	4,543,228	63,911	Apr 18 07:38 PM
O'Rourke Bridget	Director	Apr 15 '25	Sale	271.21	50	13,560	5,523	Apr 17 07:34 PM
ADAM ELSESSER	Officer	Apr 16 '25	Proposed Sale	274.35	16,560	4,543,181		Apr 16 04:41 PM
Elsesser Adam	CEO and President	Apr 02 '25	Option Exercise	30.00	41,308	1,239,240	69,060	Apr 04 08:38 PM
Elsesser Adam	CEO and President	Apr 02 '25	Sale	272.24	16,565	4,509,728	52,495	Apr 04 08:38 PM
Wilder Thomas	Director	Apr 02 '25	Sale	266.93	360	96,095	4,692	Apr 04 08:36 PM
Wilder Thomas	Director	Mar 31 '25	Sale	264.58	360	95,249	4,533	Apr 02 07:34 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Apr 01 '25	Option Exercise	22.04	600	13,224	66,953	Apr 02 07:33 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Apr 01 '25	Sale	269.11	600	161,466	66,353	Apr 02 07:33 PM
Grewal Harpreet	Director	Apr 01 '25	Sale	267.17	200	53,434	9,074	Apr 02 07:33 PM
THOMAS AND CATHARINE WILDER FA	Director	Apr 02 '25	Proposed Sale	266.93	360	96,095		Apr 02 04:04 PM
ADAM ELSESSER	Officer	Apr 02 '25	Proposed Sale	272.24	16,565	4,509,702		Apr 02 04:02 PM
Grewal Harpreet	Director	Apr 01 '25	Proposed Sale	267.17	200	53,434		Apr 01 04:07 PM
DON W KASSING	Director	Apr 01 '25	Proposed Sale	267.17	166	44,350		Apr 01 04:06 PM
THOMAS AND CATHARINE WILDER FA	Director	Mar 31 '25	Proposed Sale	264.58	360	95,249		Mar 31 04:03 PM
Bose Arani	Director	Mar 25 '25	Sale	283.77	12,000	3,405,253	314,819	Mar 27 08:01 PM
Elsesser Adam	CEO and President	Mar 19 '25	Option Exercise	30.00	27,976	839,280	44,352	Mar 21 07:32 PM
Elsesser Adam	CEO and President	Mar 19 '25	Sale	276.21	16,600	4,585,138	27,752	Mar 21 07:32 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PEN

Penumbra Inc

Upgrade your FINVIZ experience